Divestment of Product Rights (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Product Information [Line Items]
Gain (loss) on sale of product rights	$ 18.1	$ (6.0)	$ 16.5
DAYTRANA
Product Information [Line Items]
Gain (loss) on change in the fair value of divestiture contingent consideration receivable	18.1	(6.0)	10.4
Current divestiture contingent consideration receivable	11.6	13.7
Noncurrent divestiture contingent consideration receivable	27.6	28.9
Total divestiture contingent consideration receivable	39.2	42.6
Gain (loss) on sale of product rights	18.1	(6.0)	16.5
Specialty Pharmaceuticals
Product Information [Line Items]
Gain (loss) on sale of product rights	$ 18.1	$ (6.0)	$ 16.5